On August 5, 2021, PepGen, a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, announced the closing of an $112.5 crossover million financing. The funding round included existing investors RA Capital, Oxford Sciences Innovation, and CureDuchenne Ventures, and added new investors Viking, Deerfield, Qatar Investment Authority, Adage Capital Management, Samsara Biocapital, Laurion Capital Management, Tudor Investment Corporation, Gray’s Creek Capital Partners, and other leading investors. Wilson Sonsini Goodrich & Rosati represented RA Capital in the transaction.

Proceeds from the financing will be used to advance PepGen’s lead programs as well as a large pipeline of additional oligonucleotide candidates.

The Wilson Sonsini team advising RA Capital includes:

Corporate
Jennifer Fang
Amanda Creedon
Andrew Thompson

Technology Transactions
Farah Gerdes
Shefali Tandon

Please see PepGen’s press release for more information.